Literature DB >> 19632700

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

Susan Zolla-Pazner1, Sandra Cohen, Abraham Pinter, Chavdar Krachmarov, Terri Wrin, Shixia Wang, Shan Lu.   

Abstract

Studies were performed to induce cross-clade neutralizing antibodies (Abs) by testing various combinations of prime and boost constructs that focus the immune response on structurally-conserved epitopes in the V3 loop of HIV-1 gp120. Rabbits were immunized with gp120 DNA containing a V3 loop characterized by the GPGR motif at its tip, and/or with gp120 DNA with a V3 loop carrying the GPGQ motif. Priming was followed by boosts with V3-fusion proteins (V3-FPs) carrying the V3 sequence from a subtype B virus (GPGR motif), and/or with V3 sequences from subtypes A and C (GPGQ motif). The broadest and most consistent neutralizing responses were generated when using a clade C gp120 DNA prime and with the V3(B)-FP boost. Immune sera displayed neutralizing activity in three assays against pseudoviruses and primary isolates from subtypes A, AG, B, C, and D. Polyclonal Abs in the immune rabbit sera neutralized viruses that were not neutralized by pools of human anti-V3 monoclonal Abs. Greater than 80% of the neutralizing Abs were specific for V3, showing that the immune response could be focused on a neutralizing epitope and that vaccine-induced anti-V3 Abs have cross-clade neutralizing activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632700      PMCID: PMC2736369          DOI: 10.1016/j.virol.2009.05.039

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 2.  Immunogenicity and protective efficacy of influenza vaccination.

Authors:  Claude Hannoun; Francoise Megas; James Piercy
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

3.  The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

Authors:  Susan Zolla-Pazner; Ping Zhong; Kathy Revesz; Barbara Volsky; Constance Williams; Phillipe Nyambi; Miroslaw K Gorny
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

4.  Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Authors:  John R Mascola; Anna Sambor; Kristin Beaudry; Sampa Santra; Brent Welcher; Mark K Louder; Thomas C Vancott; Yue Huang; Bimal K Chakrabarti; Wing-Pui Kong; Zhi-Yong Yang; Ling Xu; David C Montefiori; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Authors:  R Shibata; T Igarashi; N Haigwood; A Buckler-White; R Ogert; W Ross; R Willey; M W Cho; M A Martin
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

Review 6.  On the specificity of antibodies.

Authors:  F F Richards; W H Konigsberg; R W Rosenstein; J M Varga
Journal:  Science       Date:  1975-01-17       Impact factor: 47.728

7.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Authors:  P N Nyambi; A Nádas; H A Mbah; S Burda; C Williams; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 9.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  24 in total

1.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

2.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Authors:  Ann J Hessell; Sean McBurney; Shilpi Pandey; William Sutton; Lily Liu; Liuzhe Li; Maxim Totrov; Susan Zolla-Pazner; Nancy L Haigwood; Miroslaw K Gorny
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

4.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

5.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Authors:  Catarina E Hioe; Terri Wrin; Michael S Seaman; Xuesong Yu; Blake Wood; Steve Self; Constance Williams; Miroslaw K Gorny; Susan Zolla-Pazner
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

6.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

7.  Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Authors:  Timothy Cardozo; Shixia Wang; Xunqing Jiang; Xiang-Peng Kong; Catarina Hioe; Chavdar Krachmarov
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

Review 8.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

9.  Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Authors:  Rajnish Kumar; Ruimin Pan; Chitra Upadhyay; Luzia Mayr; Sandra Cohen; Xiao-Hong Wang; Preetha Balasubramanian; Arthur Nádas; Michael S Seaman; Susan Zolla-Pazner; Miroslaw K Gorny; Xiang-Peng Kong; Catarina E Hioe
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

10.  Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Authors:  Preetha Balasubramanian; Rajnish Kumar; Constance Williams; Vincenza Itri; Shixia Wang; Shan Lu; Ann J Hessell; Nancy L Haigwood; Faruk Sinangil; Keith W Higgins; Lily Liu; Liuzhe Li; Phillipe Nyambi; Miroslaw K Gorny; Maxim Totrov; Arthur Nadas; Xiang-Peng Kong; Susan Zolla-Pazner; Catarina E Hioe
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.